Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
3 results loaded, newest first. End of these results.
Savara flagged new analyses of molgramostim from its IMPALA and IMPALA-2 trials in autoimmune pulmonary alveolar proteinosis for presentation at CHEST 2026. Long-term IMPALA-2 open-label data will be presented in the future, focusing on sustained efficacy and safety in treated patients. An IMPALA analysis will also be
The company said it will present a new analysis from the IMPALA clinical trial and deliver an encore presentation of long-term data on molgramostim for autoimmune pulmonary alveolar proteinosis.
For best results when printing this announcement, please click on link below: Savara to Present New Analysis from the IMPALA Clinical Trial and Deliver Encore Presentation of Long-Term Data on Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at CHEST 2026 — Company to Host Learning Theatre on aPAP with